Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
2.100
-0.010 (-0.47%)
At close: Nov 22, 2024, 4:00 PM
2.020
-0.080 (-3.81%)
After-hours: Nov 22, 2024, 7:41 PM EST
Immuneering Employees
Immuneering had 68 employees as of December 31, 2023. The number of employees decreased by 5 or -6.85% compared to the previous year.
Employees
68
Change (1Y)
-5
Growth (1Y)
-6.85%
Revenue / Employee
n/a
Profits / Employee
-$853,950
Market Cap
62.27M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 68 | -5 | -6.85% |
| Dec 31, 2022 | 73 | 9 | 14.06% |
| Dec 31, 2021 | 64 | 38 | 146.15% |
| Dec 31, 2020 | 26 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| InterCure | 270 |
| Champions Oncology | 210 |
| Celularity | 120 |
| AlloVir | 112 |
| Cue Biopharma | 53 |
| Spero Therapeutics | 46 |
| Cellectar Biosciences | 20 |
| Milestone Scientific | 17 |
IMRX News
- 10 days ago - Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 2 months ago - Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients - GlobeNewsWire
- 3 months ago - Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 4 months ago - Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer - GlobeNewsWire
- 6 months ago - Immuneering to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 7 months ago - Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 7 months ago - Immuneering Recognizes Melanoma Awareness Month - GlobeNewsWire
- 8 months ago - IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models - GlobeNewsWire